Lemtrada

Lemtrada

August 26, 2019August 26, 2019

Link Between Lemtrada, Mortality More Common Than Previously Reported

Lemtrada, News

Treatment with Lemtrada (alemtuzumab) is associated with the death of patients with relapsing-remitting multiple sclerosis (RRMS) more often than previously reported and appears to be most common during the first ... Read more

July 17, 2018July 23, 2018

My Lemtrada Journey: A Little Dip on the Roller Coaster

Columns, Lemtrada, The MS Wire - A Column by Ed Tobias

I’m now three months past my second round of Lemtrada treatments, so it’s time for an update. I began Lemtrada (alemtuzumab) in December 2016, hoping it will be the last ... Read more

May 2, 2018May 16, 2018

#AAN2018 — Lemtrada Sustains Long-Term Benefits for RRMS Patients, TOPAZ Study Shows

Lemtrada, News

Lemtrada (alemtuzumab) can sustain reduced activity and prevent progression of relapsing-remitting multiple sclerosis (RRMS) for more than seven years, clinical data from the CARE-MS extension trial shows. Findings were recently presented ... Read more

April 27, 2018May 1, 2018

Tricks of the Trade

Columns, Fall Down, Get Up Again- a Column by John Connor, Lemtrada

I saw my neurologist a few weeks ago for what was effectively an emergency meeting. I’d had the customary two rounds of Lemtrada (alemtuzumab) and still had a relapse. We ... Read more

April 26, 2018May 1, 2018

#AAN2018 – Cladribine Injections Deplete Number of Memory B-cells in RRMS, Study Shows

Lemtrada, News

Cladribine treatment leads to a selective depletion of memory B-cells in patients with relapsing-remitting multiple sclerosis (RRMS), researchers report. The results are in the presentation “Cladribine for the Effective Control of Multiple Sclerosis ... Read more

April 13, 2018May 1, 2018

Acute Acalculous Cholecystitis Linked to Lemtrada Use in RRMS Patients, FDA Reports

Lemtrada, News

Acute acalculous cholecystitis (AAC) is a rare but potentially life-threatening adverse effect linked to treatment with Lemtrada (alemtuzumab) in patients with relapsing-remitting multiple sclerosis (RRMS), according to a U.S. Food and ... Read more

April 5, 2018March 11, 2019

MS Path 2 Care Program Aims to Empower Patients to Be Active in Healthcare Journey

Aubagio, Lemtrada, News, Ocrevus

In the first year after being diagnosed with multiple sclerosis (MS) in 1997, Ann Borsellino basically withdrew from life, rarely even leaving her bedroom. Knowing little about the disease, she assumed ... Read more

March 23, 2018March 11, 2019

It Shouldn’t Be This Hard to Get Our MS Medications

Aubagio, Columns, Lemtrada, Ocrevus, The MS Wire - A Column by Ed Tobias

I got a phone call from my MS One to One nurse, Lynn, today. One to One is the patient support service provided by Sanofi Genzyme for patients on the ... Read more

February 16, 2018May 1, 2018

Having a Swell Time

Columns, Fall Down, Get Up Again- a Column by John Connor, Lemtrada

The thing about becoming increasingly immobile is that your consumption of TV, radio, podcasts, books and, indeed, anything written goes up immeasurably. Luckily, one of the creative explosions in the recent ... Read more

February 9, 2018May 1, 2018

#ACTRIMS2018 – Third Course of Lemtrada Improves Relapse, Disability in MS Patients, CARE-MS II Trial Shows

Lemtrada, News

Multiple sclerosis (MS) patients who experience a relapse after two courses of Lemtrada (alemtuzumab) treatment showed improvements in relapse rate and disability after a third Lemtrada course, according to results of the CARE-MS II ... Read more

January 19, 2018May 21, 2018

Heavy-hitting MS Therapies Now Being Used Sooner for Some Patients

Columns, Lemtrada, Ocrevus, The MS Wire - A Column by Ed Tobias

I’m sitting in Florida and the start of spring training is only about six weeks from now, so please forgive a baseball analogy: The heavy-hitters of the MS-fighting treatments, the ... Read more

December 15, 2017May 21, 2018

Ocrevus’ Use Continues Rising, with RRMS Patients Receiving the Most Attention

Lemtrada, News, Ocrevus

U.S. neurologists are increasingly prescribing Genentech’s Ocrevus (ocrelizumab) to their multiple sclerosis patients, Spherix Global Insights reports. Another good sign for Genentech is that, in just three months, neurologists have increased ... Read more

November 17, 2017May 1, 2018

The Case of the Worried Patient

Columns, Fall Down, Get Up Again- a Column by John Connor, Lemtrada

Hypochondria grabs, and it’s very difficult to shake. I spent the past three days eliminating potential reasons for struggling more than usual. Hopefully, it was a urinary tract infection (UTI) ... Read more

October 27, 2017May 1, 2018

#MSParis2017 – Lemtrada Shows Good Safety and Lasting Efficacy Over 7 Years, Doctor Says in Interview

Lemtrada, News

Lemtrada (alemtuzumab) remains a “game-changer” of a treatment for relapsing multiple sclerosis (MS), with benefits continuing and no new side effects seen in a study of its use that now ... Read more

October 27, 2017May 1, 2018

#MSParis2017 – Early High-Efficacy Treatment Reduces Disability Accumulation in Young MS Patients

Lemtrada, News

While early use of high-efficacy treatments lowers relapse rates among patients with relapsing-remitting multiple sclerosis (MS) compared to lower-efficacy ones, starting these therapies earlier may only impact the accumulation of ... Read more

October 26, 2017May 1, 2018

MS Alphabet: Lesion, LP, Leukocytes, and Other ‘L’ Words

Columns, Lemtrada, MS in Moderation – a Column by Tamara Sellman

Editor’s note: Tamara Sellman continues her occasional series on the MS alphabet with this first of two columns about terms starting with the letter L. Symptoms of MS Lesion Lesions ... Read more

October 26, 2017May 1, 2018

#MSParis2017 – Lemtrada and Tysabri More Efficient Than Older Injectables in Preventing SPMS Onset, Study Finds

Lemtrada, News

Sanofi Genzyme‘s Lemtrada (alemtuzumab) and Biogen‘s Tysabri (natalizumab) are more effective in preventing conversion to secondary progressive multiple sclerosis (SPMS) compared to older injectable drugs, researchers from the University of ... Read more

October 23, 2017March 20, 2019

#MSParis2017 – Sanofi to Present Long-term Data on Lemtrada and Aubagio Use

Aubagio, Lemtrada, News

New data on how Lemtrada and Aubagio perform in a real-world setting will be the focus of Sanofi Genzyme when the company showcases its research at the upcoming ... Read more

October 6, 2017May 1, 2018

Lemtrada Prevented Progression of Multiple Sclerosis for Five Years, Study Shows

Lemtrada, News

Two short courses of Lemtrada prevented multiple sclerosis from becoming active and progressing for five years, a study reported. Lemtrada’s maker, Sanofi-Genzyme, said the study covered the two-year CARE-MS II Phase 3 clinical ... Read more

October 2, 2017May 1, 2018

Long-term Lemtrada Treatment Benefits Demonstrated in Extension Study

Lemtrada, News

A five-year study demonstrated that Sanofi-Genzyme’s Lemtrada (alemtuzumab) provides long-term benefits for relapsing-remitting multiple sclerosis patients, reducing relapse rates and preventing the progression of the disease. Importantly, most patients required only ... Read more

September 15, 2017May 1, 2018

My Lemtrada Journey: At 9 Months, a Cane Tells a Tale

Columns, Lemtrada, The MS Wire - A Column by Ed Tobias

Back in May, when I updated everyone about my Lemtrada treatment at six months post-infusion, I began with a question my wife asked: “Do you think you’re walking better?” And, ... Read more

July 28, 2017May 21, 2018

MS Therapies: What’s Hot, What’s Not

Columns, Lemtrada, Ocrevus, The MS Wire - A Column by Ed Tobias

Ocvevus (ocrelizumab) is off to a running start, Tecfidera (dimethyl fumarate) leads the pills and the four injectable multiple sclerosis drugs are being used by fewer MS patients. But Copaxone ... Read more

July 21, 2017May 1, 2018

The Mouth that Roared

Columns, Fall Down, Get Up Again- a Column by John Connor, Lemtrada

After 10-odd ― indeed, increasingly odd ― years, I presumed I’d become something of a gnarled hand at MS. If you read about something on practically a daily basis, you ... Read more

July 21, 2017July 23, 2018

Do MS Patients in the UK Get the Right Treatment Quickly Enough?

Columns, Lemtrada, The MS Wire - A Column by Ed Tobias

About two years ago, a report by the European Multiple Sclerosis Platform stated that only 21% of MS patients in the United Kingdom were receiving any kind of disease-modifying therapy. ... Read more

June 26, 2017May 1, 2018

RRMS Patients at Risk of PML Can Safely Switch from Tysabri to Lemtrada

Lemtrada, News

Lemtrada (alemtuzumab) may be an effective option for relapsing-remitting multiple sclerosis (RRMS) patients withdrawing from prior treatment with Tysabri (natalizumab), an Italian study shows. The study, “High-Risk PML Patients Switching ... Read more

June 13, 2017May 1, 2018

Unpublished Data May Point to Link Between Lemtrada and Other Autoimmune Diseases in MS Patients

Lemtrada, News

Previously unpublished results of clinical trials of Lemtrada (alemtuzumab) appears to contain key information as to why many multiple sclerosis patients who use it develop other autoimmune diseases. Researchers looked at ... Read more

June 5, 2017May 1, 2018

MS News That Caught My Eye: An Acne Drug, a High-Cost Gel, Good News About Lemtrada, and Getting Off MS Drugs

Columns, Lemtrada, The MS Wire - A Column by Ed Tobias

In case you missed them, here are some news stories that appeared in MS News Today that caught my eye over the past week. Acne Therapy Reduces Rate of Multiple Sclerosis ... Read more

June 2, 2017May 1, 2018

Lemtrada II: My Right Foot (Hopefully)

Columns, Fall Down, Get Up Again- a Column by John Connor, Lemtrada

Read John Connor’s previous column, “Lemtrada I: This Island Couch.” Apologies for the pic of my edema–riddled right foot. If I put whiskers on it, my big toe could do ... Read more

May 31, 2017May 1, 2018

#CMSC17 – Lemtrada’s 2 Year Therapy in RRMS Sustains Efficacy for Over 6 Years Without Additional Treatment

Lemtrada, News

Taking Lemtrada (alemtuzumab) for two years inhibited magnetic resonance imaging (MRI) disease activity in patients with relapsing-remitting multiple sclerosis (RRMS) for more than six years, the CARE-MS I clinical trial extension study ... Read more

May 26, 2017May 1, 2018

#CMSC17 – Relapse After First Lemtrada Course No Indication of Poor Long-Term Outcome, Study Finds

Lemtrada, News

Multiple sclerosis (MS) patients who experienced a relapse between their first and second rounds of Lemtrada (alemtuzumab) had good treatment outcomes over the long run, according to a Phase 3 ... Read more

May 26, 2017May 1, 2018

Lemtrada I: This Island Couch

Columns, Fall Down, Get Up Again- a Column by John Connor, Lemtrada

The latest drug media storm to erupt in Britain is “Spice,” which causes users to become living statues. Exactly a year ago, I became a living statue for six weeks, ... Read more

April 28, 2017May 21, 2018

Lemtrada Might Outperform Ocrevus in Preventing MS Relapses, Italian Researchers Say

Lemtrada, News, Ocrevus

Lemtrada (alemtuzumab) may be more effective in preventing relapses in multiple sclerosis patients than the newly approved Ocrevus (ocrelizumab), according to a study presented April 28 at the American Academy of Neurology ... Read more

April 26, 2017March 20, 2019

Sanofi Genzyme to Present New Data on MS Treatments Lemtrada and Aubagio

Aubagio, Lemtrada, News

Sanofi Genzyme will present new results on follow-up studies of its products Lemtrada (alemtuzumab) and Aubagio (teriflunomide), both of which have been approved for the treatment of relapsing-remitting multiple sclerosis ... Read more

April 20, 2017May 21, 2018

AAN Annual Meeting Offers First Ocrevus Data Update Since MS Therapy’s Approval by FDA

Faith of the Mustard Seed - a Column by Debi Wilson, Lemtrada, News, Ocrevus

New data on the recently approved multiple sclerosis (MS) drug Ocrevus (ocrelizumab) will be presented at the upcoming American Academy of Neurology (AAN) Annual Meeting 2017, which will take place ... Read more

April 19, 2017May 1, 2018

Sanofi Genzyme to Discuss Three Multiple Sclerosis Therapies at Boston Event

Lemtrada, News

Sanofi Genzyme will discuss three of its multiple sclerosis therapies at the American Academy of Neurology annual meeting in Boston, April 22-28. The presentations will cover two approved treatments for relapsing MS – ... Read more

March 28, 2017May 1, 2018

My MS Is Getting to Be a Pain, Literally

Columns, Lemtrada, The MS Wire - A Column by Ed Tobias

For most of the 36 years since I was diagnosed with multiple sclerosis I’ve not been bothered by pain. Just lucky, I guess. Until last month. Suddenly, I’ve developed pain ... Read more

February 23, 2017May 1, 2018

#ACTRIMS2017 – Lemtrada Maintains Durable Positive Effects in MS Without Additional Treatment

Lemtrada, News

Two Phase 3 clinical trials investigating the long-term effects of Lemtrada (alemtuzumab) in multiple sclerosis (MS) patients showed the drug maintained improved outcomes, even in the absence of further treatment. ... Read more

February 6, 2017May 1, 2018

Switching From Gilenya to Lemtrada Seen to Trigger Disease Activity in Some MS Patients

Lemtrada, News

Switching from Gilenya (fingolimod) to Lemtrada (alemtuzumab) triggers significant and unexpected disease activity in some patients with multiple sclerosis (MS), according to a study published in the scientific journal Neurology ... Read more

January 27, 2017May 1, 2018

My Lemtrada Coaster Has Been Rolling

About two weeks ago I wrote about my roller-coaster ride being pretty smooth since my first round of Lemtrada infusions ended in early December. Well, the loops are now looping. ... Read more